
Opinion|Videos|August 29, 2024
Guidance on Transitioning from TNFi to Non-TNF Targeted Therapies
Experts discuss American College of Rheumatology guidelines on transitioning patients from TNF inhibitors to non-TNF targeted therapies like Janus kinase inhibitors, as well as factors influencing treatment switching decisions in clinical practice.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- For patients receiving tumor necrosis factor (TNF) inhibitors, please describe American College of Rheumatology guidance on switching to a non-TNF targeted therapy, such as Janus kinase inhibitors, vs cycling.
- In your own practice, what factors would make you consider switching?
Advertisement
Related to this article

A FIBRONEER-ILD subgroup analysis presented at ACR 2026 found no heterogeneity in nerandomilast's effect on FVC decline or clinical events.

Secukinumab 150 mg doubled week-52 sustained remission vs placebo in REPLENISH, making it the first anti-IL-17 biologic approved for PMR.

Afimetoran achieved SRI-4 response rates of 64.1% to 67.8% vs 34.4% with placebo in a phase 2 SLE trial.

The 200-mg dose improved ACR20 response vs placebo at week 16 in biologic-naïve patients, while the 400-mg dose added no benefit.

An international IgG4ward! Foundation panel issued 28 treatment statements for IgG4-related diseases, with consensus reached on 22.

In 33 patients with myositis-associated ILD from FIBRONEER-ILD, nerandomilast numerically slowed FVC decline and lowered progression risk.

RESET-RA 24-month data show sustained clinical responses with vagus nerve stimulation in patients with treatment-experienced RA.
Advertisement
Advertisement

